Plasmid-acquired carbapenemases in Enterobacteriaceae, which were first discovered in Europe in the 1990s, are now increasingly being identified at an alarming rate. Although their hydrolysis spectrum may vary, they hydrolyse most b-lactams, including carbapenems. They are mostly of the KPC, VIM, NDM and OXA-48 types. Their prevalence in Europe as reported in 2011 varies significantly from high (Greece and Italy) to low (Nordic countries). The types of carbapenemase vary among countries, partially depending on the cultural/ population exchange relationship between the European countries and the possible reservoirs of each carbapenemase. Carbapenemase producers are mainly identified among Klebsiella pneumoniae and Escherichia coli, and still mostly in hospital settings and rarely in the community. Although important nosocomial outbreaks with carbapenemase-producing Enterobacteriaceae have been extensively reported, many new cases are still related to importation from a foreign country. Rapid identification of colonized or infected patients and screening of carriers is possible, and will probably be effective for prevention of a scenario of endemicity, as now reported for extended-spectrum b-lactamase (mainly CTX-M) producers in all European countries.
Introduction
Carbapenemases are enzymes that are able to hydrolyse nearly all b-lactam antibiotics, including carbapenems. They are classified into different molecular classes (A, B and D), and have become epidemiologically important in different parts of the world, including Europe, in recent years [1] [2] [3] [4] . Most carbapenemases are plasmid-mediated, and have been mainly reported in Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii ( Table 1) .
In 2005, Walsh et al. [5] published a review article entitled 'Metallo-b-lactamases: the quiet before the storm?' Although they specifically reviewed the biochemical and genetic characterization of metallo-b-lactamases (MBLs), they also pointed out that the continued spread of carbapenemases worldwide would result in a clinical catastrophe and could cause a future public health crisis. Unfortunately, the current epidemiological situation in Europe confirms this prediction at a level that is even worse than expected. At the time of that review, most of the carbapenemases were confined to P. aeruginosa, only anecdotal reports of currently important carbapenemases such as KPCs belonging to class A [6] or OXA-48 belonging to class D [7] had been published, and NDM-1 belonging to class B had not been described [8] .
In this review, we describe the evolving situation of carbapenemase-producing Enterobacteriaceae (CPE) in Europe, highlighting epidemiological data from representative countries.
From Extended-spectrum b-Lactamases (ESBLs) to Carbapenemases
The interest in b-lactam resistance in Enterobacteriaceae during the 2000s was dominated by the increase in the number of Enterobacteriaceae producing ESBLs, particularly the CTX-M enzymes [9] . Characterization of the genetic environment of the bla CTX-M genes and the respective plasmid carriers revealed the existence of efficient genetic machineries contributing to the spread of these resistance determinants. In addition, data obtained from epidemiological typing tools such as multilocus sequence typing revealed the spread of specific Escherichia coli and Klebsiella pneumoniae clones expressing ESBL phenotypes, even in the community setting [10] [11] [12] . Cumulative experience with ESBL producers supports the idea that, once the prevalence surpasses a critical threshold, their eradication from bacterial communities is nearly impossible.
At present, the interest in b-lactamases has turned to carbapenemases, particularly in Enterobacteriaceae [1, 3, 4, 13] . The emergence of ESBLs and that of carbapenemases have had different epicentres, but lately they have spread to different parts of the world. ESBLs appeared almost simultaneously in Europe (Germany) and South America (Argentina), whereas carbapenemases appeared mainly in Asia (Japan and India) and North America (USA) [4] . With ESBLs, it seems that, after quiet and continuous spread, outbursts occurred in many parts of the world, including Europe [14] . This could also have been the 
Carbapenemases in Europe: a north-south distribution?
In a summary from a meeting on carbapenem-non-susceptible Enterobacteriaceae published in 2010 [16] , European countries were classified into a numerical staging system according to the epidemiological situation. This scale includes: 0, no cases reported; 1, sporadic occurrence; 2a, single-hospital outbreaks; 2b, sporadic hospital outbreaks; 3, regional outbreaks; 4, interregional spread; and 5, endemic situation. At the time of that summary, July 2010, two countries each were graded 5 (Greece and Israel) and 4 (Italy and Poland), three were graded 3 (France, Germany, and Hungary), three were graded 2a (Belgium, Spain, and England/ Wales), and five were graded 2b (Cyprus, The Netherlands, Norway, Scotland, and Sweden). Other European countries were graded 1 or 0. The situation changed during 2011, as the number of reports from different European countries increased dramatically. Fig. 1 shows the current situation in different European countries according to this epidemiological scale, and carbapenemase types in different countries or geographical areas. According to the EARS-Net surveillance study (http:// ecdc.europa.eu/en/activities/surveillance/EARS-Net/database/ Pages/database.aspx), antimicrobial resistance in northern European countries is lower than in southern European countries. This is true for ESBL-producing organisms as well as for methicillin-resistant Staphylococcus aureus, but only partially true for carbapenemase-producing E. coli and K. pneumoniae (Fig. 2 ). These figures indicate that different factors might be influencing the emergence and spread of carbapenemases than that of ESBLs and/or methicillinresistant S. aureus. Antimicrobial use and different policies and/or implementation of infection control measures can be only partly responsible for these differences. Importation of carbapenemases from specific areas in Europe as a 
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Cantó n et al. Carbapenemase-producing Enterobacteriaceae in Europe consequence of cross-border transfer of patients, travel, medical tourism and refugees might play also an important role in this outburst [15, 19, 20] . This has been clearly demonstrated for carbapenemases of different molecular classes, including KPC [21, 22] , NDM-1 [23] , and OXA-48 [24] [25] [26] .
Emergence and Spread of CPE in Different European Countries
Most CPE data for Europe have come from microbiological studies carried out during the emergence of these isolates in specific countries or when describing outbreaks. These data are not always in agreement with local and supranational surveillance reports. For these studies, clinical breakpoints are used, and they do not introduce concepts to discriminate non-wild-type populations from those with high-level or low-level resistance mechanisms. This can be the case for enterobacterial isolates with low-level expression of carbapenemases [27, 28] .
Implementation of national guidelines for reporting multidrug-resistant (MDR) organisms may influence communication and publishing on the emergence of CPE. Some European countries have frequently reported the emergence of these isolates, whereas in others no epidemiological information is available. Nevertheless, in these countries information has became available when patients have been transferred to the former countries. This has been, for instance, the case for the detection of NDM-1 in the Balkans [15] . Moreover, countries with very active investigators have a large number of reports, despite their countries having a lower prevalence than others. This is, for instance, the case for France and UK as compared with other countries. The current information on CPE in Europe is presented below.
Greece
According to the data of the EARS-Net, Greece is the European country with the highest incidence of CPE isolates, and has been considered to be the epicentre of the spread of VIM-producing Enterobacteriaceae, mainly K. pneumoniae, to other EU countries [29, 30] . Recent reports of the EARS-Net database (http://ecdc.europa.eu/en/activities/surveillance/ EARS-Net/database/Pages/database.aspx) show that up to 49% of K. pneumoniae invasive isolates in Greece exhibit resistance to carbapenems, but this percentage can be even higher in intensive-care units (ICUs) [31] .
In November 2001, an E. coli strain exhibiting decreased susceptibility to carbapenems was isolated from a hospitalized patient [32] . This strain was the first CPE isolate obtained in Europe. The strain carried a self-transferable plasmid coding for VIM-1. The bla VIM-1 gene, along with the aacA7, dhfrI and aadA genes, was included as a gene cassette in a class 1 integron (In-e541). Soon, VIM-1-producing E. coli strains were isolated in Crete [33] with bla VIM-1 genes located in a class 1 integron that was different from the initially characterized one. In 2002, distinct VIM-1-producing K. pneumoniae strains exhibiting various carbapenem resistance levels were recovered from ICU patients in three tertiary-care institutions in Athens [34] . Since then, polyclonal outbreaks of VIM-positive K. pneumoniae isolates have been described in hospitals throughout the country [31, 35] . The majority of the VIM producers harboured variants of a selftransmissible plasmid of the IncN family that contained Ine541 [36] . Nevertheless, the bla VIM-1 gene was increasingly found in other replicons as well as chromosomes of enterobacterial species other than K. pneumoniae and E. coli. Also, reshuffling of the bla VIM gene cassette in various class 1 integrons and the emergence of novel bla VIM variants have occurred over time [37] [38] [39] .
KPC-2-producing K. pneumoniae was first reported in Greece in 2008 [40] , although the introduction of KPC-2-producing K. pneumoniae in this country started 1 year before, as the first outbreak occurred in Crete in 2007 [41] . Since then, the continuous spread of these isolates, later demonstrated to belong to the sequence type (ST)258 lineage [42] , has led to a nationwide epidemic. The bla KPC-2 gene is commonly carried by plasmids of similar size (c. 100 kb) belonging to the FII k incompatibility group and associated mainly with the Tn4401a isoform, whereas the Tn4401b isoform has been sporadically detected.
Today, ST258 is still predominant among KPC-positive K. pneumoniae isolates, but additional KPC-producing clones (ST147, ST383, ST133, ST274, and ST323, among others) have emerged. It is of note that ongoing monitoring of carbapenem-non-susceptible K. pneumoniae has revealed the emergence of clones expressing both VIM and KPC enzymes, but at present their frequency of isolation is low. Also, resistance to colistin has already emerged, and pan-drug resistant isolates are being increasingly reported [43] [44] [45] . Finally, outbreaks caused by E. coli strains producing KPC-2 in longterm-care facilities have recently been reported [46] . These findings show the potential of the KPC-positive Enterobacteriaceae isolates to spread outside the hospital environment and to circulate in the community, as has occurred with VIM producers in Spain [47] (R. Cantó n and P. Ruiz-Garbajosa, unpublished data). Unlike in other European countries, KPC-3, NDM and OXA-48 producers have not yet been reported in Greece.
Turkey
Resistance in Turkey is not currently recorded in the EARSNet database. Nevertheless, in the last available data from this surveillance study before transition to the ECDC (formerly the EARSS) and corresponding to 2008, carbapenem resistance in K. pneumoniae was 3%, similar to that in Italy and the Balkan countries (http://ecdc.europa.eu/en/activities/ surveillance/EARS-Net/database/Pages/database.aspx). This situation, as that in other European countries, might have changed in the last few years with the increasing prevalence of CPE.
The most important carbapenemase in Turkey is OXA-48. First detected in 2001 in Istanbul in K. pneumoniae [7] , it is now well disseminated in the Mediterranean and western European countries [4] . This class D carbapenemase has been found in different Enterobacteriaceae, such as Citrobacter freundii [48] , Providencia rettgeri, and Enterobacter cloacae [49] , and even in E. coli [50, 51] . Although the majority of these descriptions were associated with single cases, important outbreaks have also been described [52] . In addition, OXA-48 has been found in patients transferred from Turkey to other European countries [24] . Further analysis of the OXA-48-producing isolates demonstrated that this enzyme was not exclusively linked with a single clone, and that the bla OXA-48 gene was associated with either transposon Tn1999 or transposon Tn1999.2 within transferable nontypeable plasmids of 70 or 150 kb [53] . Despite these observations, recent data on OXA-48-producing K. pneumoniae isolates in western European countries showed the dissemination of a single clone that is also found in Morocco [53] . OXA-48 producers might be also circulating in the community in Turkey (P. Nordmann, unpublished data). [54] and in P. aeruginosa [55] during this period. Moreover, it might have coexisted with the VIM-1 that was later reported in P. aeruginosa [56] and in K. pneumoniae [57] . Remarkably, VIM-1-producing and SHV-12-producing K. pneumoniae isolates were identified in Norway in a patient with a recent history of hospitalization in Turkey [58] . Other MBL detected in Enterobacteriaceae was IMP-1 in K. pneumoniae in 2003 [59] [63, 64] . In early 2006, small polyclonal outbreaks of KPC-2-producing K. pneumoniae occurred in Israeli hospitals, shortly followed by a multicentre outbreak caused primarily by a single KPC-3 clone termed clone Q as assessed by pulsed-field gel electrophoresis [65, 66] . The epidemic clone Q was later shown to have a similar pattern to that of isolates implicated in large US outbreaks since the early 2000s [67] , and has been shown to belong to the pandemic clone ST258, suggesting importation from the USA [68] . The nationwide nature of this outbreak was identified only in early 2007, and a national intervention to limit the spread of KPC-producing Enterobacteriaceae was initiated only after 1275 cases had already occurred in 27 acute-care hospitals (175 cases per million population). At the peak of the outbreak, 186 new cases were identified monthly. Indeed, the EARSS reports documented a rise of carbapenem resistance in Klebsiella isolates causing bacteraemia from 0% to 22% between 2005 and 2008. Following the intervention, the incidence of clinical cases of carbapenem-resistant Enterobacteriaceae in acutecare hospitals stabilized at 40 cases per month by mid-2008 (5.3 cases per million population per month). The outbreak and the national intervention are described in detail elsewhere [69] . In parallel, it was observed that a large reservoir of carbapenem-resistant Enterobacteriaceae carriers was created in long-term-care facilities [70] . Currently, carbapenemresistant Enterobacteriaceae rarely spread in the community. In almost all Israeli acute-care hospitals, the risk of acquiring CPE during a hospital stay is minimal (c. 1/1000 admissions); however, the endemicity is maintained by the large reservoir created in the long-term-care setting. KPC enzymes have not been detected in Gram-negative non-fermenters in Israel.
MBLs in
Apart from KPC, a few cases of OXA-48 and NDM-1 have been introduced into Israel by tourism [71] , and single cases have been detected with no apparent foreign travel relationship.
Italy, Croatia, and Slovenia
Italy was the first European country to report acquired carbapenemases in Gram-negatives during the late 1990s. These early reports included IMP-2 from A. baumannii [72, 73] and VIM-1 from P. aeruginosa [74] and Achromobacter xylosoxidans isolates [75] , and represented the first descriptions of these enzymes. Recently, the bla VIM-1 determinant has been detected in a stored strain of Pseudomonas mosselii isolated in Italy in 1994 [76] , suggesting that the influx of this carbapenemase gene in the clinical setting dates back to least the early 1990s.
The first report of CPE from Italy dates back to the early 2000s, with sporadic isolates of K. pneumoniae and Enterobacter cloacae producing VIM-4 [77] . Since then, several reports have documented the presence of various Enterobacteriaceae (mostly K. pneumoniae, Enterobacter, and E. coli) producing VIM-1-like enzymes [78] [79] [80] [81] [82] [83] [84] [85] . However, such VIMproducing Enterobacteriaceae have not undergone wide dissemination, unlike that observed in Greece during the same period, and their spread remains low overall and mostly limited to sporadic cases or small clonal outbreaks, as was documented by a recent nationwide survey (G. M. Rossolini, unpublished data). Nevertheless, VIM enzymes have been associated with E. coli that are also associated with dissemination of ESBLs, such as ST131 [86] .
A different evolution has been observed with K. pneumoniae producing KPC-type enzymes. Reported for the first time in late 2008, where the likely source was a medical trainee from Israel [87] , KPC-producing K. pneumoniae has since undergone rapid and extensive dissemination in this country, with several reports of hospital outbreaks [88] [89] [90] [91] [92] [93] [94] [95] . The abrupt and remarkable increase in carbapenem resistance rates in K. pneumoniae recently reported by the EARSNet surveillance system for Italy (from 1% to 2% during the period 2006-2009 to 15% in 2010) (http://ecdc.europa.eu/en/ activities/surveillance/EARS-Net/database/Pages/database.aspx) appears to be mostly related to the countrywide dissemination of KPC-producing K. pneumoniae, as shown by results from a recent countrywide survey (G. M. Rossolini, unpublished data). As in Greece, multifocal emergence of colistinresistant isolates of KPC-producing K. pneumoniae has been observed [92] (Giani et al., 51st ICAAC, 2011, Abstract C2669b), which is a matter of major concern, as colistin is among the few drugs that retain activity against these organisms, and is a cornerstone of antimicrobial chemotherapy for infections caused by these organisms.
Most recently, isolates of E. coli and K. pneumoniae producing NDM-1 [96, 97] and OXA-48 [98] , of likely cross-border origin, have also been reported in Italy, but the dissemination of these carbapenemases appears to be still very limited.
Few data are available on the dissemination of acquired carbapenemases in countries bordering the eastern coast of the Adriatic Sea. Most of them are associated with P. aeruginosa and Acinetobacter [99] [100] [101] [102] , but a case of OXA-48-producing K. pneumoniae imported from Libya has recently been found in Slovenia [103] . It is of note that dissemination of NDM-1 is highly suspected in this area, as there are different reports of the isolation of NDM-1-producing Enterobacteriaceae in patients from Balkan countries but admitted to other European countries [15, 104] .
Spain and Portugal
As in other Mediterranean countries (Greece, Italy, and France), the first description of CPE in Spain concerned the VIM type, and was published in 2005 [105] . In this study, an E. coli isolate from a urinary tract infection and a K. pneumoniae isolate, recovered in 2003 during a surveillance study of faecal ESBL carriers in Barcelona, were shown to produce VIM-1. Since then, continuous penetration of different carbapenemases from different molecular classes has been observed, and both sporadic cases and important outbreaks have been described [106] [107] [108] [109] [110] .
The first outbreak involving VIM-1 occurred at Ramó n y Cajal University Hospital (Madrid) in 2005 and 2006 [106] . Twenty-five patients (52% from the ICU) were infected and/ or colonized with single or multiple MBL-producing Enterobacteriaceae isolates, including K. pneumoniae, E. cloacae, E. coli, and Klebsiella oxytoca). Clonal analysis revealed a complex population structure, as all K. pneumoniae isolates belonged to the same clone but different patterns were found among the Enterobacter cloacae isolates. This complexity was even higher when the genes and plasmids surrounding the bla VIM-1 gene were characterized. The bla VIM-1 gene was detected within a 4.0-kb class 1 integron (In113, bla VIM-1 -aacA4-dfrII-aadA1-catB2) in K. pneumoniae and E. coli, and within a 2.5-kb class 1 integron (In110, bla VIM-1 -aacA4-aadA1) in E. cloacae and K. oxytoca isolates. A 60-kb plasmid belonging to the IncI1 group was detected in the epidemic VIM-1-producing K. pneumoniae clone, whereas plasmids of 300 or 435 kb belonging to the IncH12 group were found among E. cloacae isolates. Interestingly, the K. pneumoniae and E. coli isolates also produce the ESBL SHV-12. Moreover, class 1 integrons were associated with defective Tn402 variants also found in VIM-1-producing P. aeruginosa isolates from the same institution, indicating potential interspecies spread of different genetic determinants [111] .
In 2009, the Spanish Network Research of Infectious Disease (REIPI) performed a surveillance study involving 35 hospitals, with the aim of investigating the epidemiology of CPE isolates in Spain (Miró et al., XIV Congress of the Spanish Society of Infectious Diseaeses and Clinical Microbiology, 2010, Abstract 706). Only class B carbapenemase producers were found (VIM-1 and IMP-22) in specific areas (Madrid, Catalonia, Andalusia, and Balearic Islands), with a local prevalence of <0.2% of tested isolates. This situation might have changed, as several descriptions of outbreaks caused by VIM producers have been published since then, as well as sporadic cases affecting non-hospitalized patients [47, [110] [111] [112] [113] [114] [115] . One of these outbreaks was associated with the ST15 clone previously associated with the spread of CTX-M-15 in central Europe [110] . In addition, KPC-3 in K. pneumoniae [107] , but not belonging to ST258, and KPC-2 in C. freundii [108] , and NDM-1 in E. coli and K. pneumoniae [26, 109, 116] have also emerged. Very recently, an outbreak caused by a porin-deficient K. pneumoniae isolate co-producing OXA-48 and CTX-M-15 was recognized [26] . The index case was a patient transferred from an ICU in a hospital in Marrakech (Morocco) to Barcelona. Sequence typing study revealed that the OXA-48-producing, CTX-M-15-producing K. pneumoniae isolate belonged to the ST101 clone that was previously found in North African countries and that was responsible from the spread of this enzyme in other European countries [117] . All of these descriptions confirmed the dissemination of carbapenemase-producing isolates in Spain, which can even be found in hospital sewage water [118] .
In Portugal, with the exception of one report of a VIM-2-producing K. oxytoca isolate, reports of VIM enzymes are restricted to P. aeruginosa [119] . KPC enzymes have not been described in clinical Enterobacteriaceae isolates, but a KPC-producing E. coli isolate was very recently found in the aquatic environment [120] .
France and Switzerland
The first description of CPE in France was in 1993, i.e. NmcA in E. cloacae [121] , the first carbapenemase to be identified in Enterobacteriaceae. Then, a VIM-1-producing K. pneumoniae isolate also co-producing SHV-5 was reported in 2004 and subsequently in a nosocomial outbreak [29, 122] . The bla VIM-1 gene was part of a class 1 integron that also included the aac6, dhfrI and aadA genes, and was similar to those reported from strains isolated in Greece. The index case was a patient transferred from Greece and identified on admission as a CPE faecal carrier. This isolate spread to other patients, but was not longer isolated after implementation of infection control barrier precautions. Also, VIM-19 with extended carbapenemase activity was isolated from E. coli and K. pneumoniae from a patient transferred from Algeria [123] . VIM-1-producing isolates have rarely been reported, and have always been associated with patients transferred from Greece, whereas IMP-producing Enterobacteriaceae have only been isolated once in France. However, a study performed in 2010 showed penetration of VIM-1 and IMP-1 [124] . This study addressed the prevalence of MDR Gram-negative bacilli and ESBL-producing isolates in stool specimens obtained from patients hospitalized for acute diarrhoea in a university hospital during a non-outbreak situation. Surprisingly, it revealed a high prevalence of CPE faecal carriers (2.6% of patients). All isolates were E. cloacae with VIM-1 or IMP-1.
The first identification of NDM-1 in France was in April 2009. It corresponded to an imported E. coli isolate from India [125] . Subsequently, most NDM-1 cases were of Indian origin, but there were also cases from Iraq and Serbia [126, 127] . In addition, in 2011, the first reported case of community-acquired NDM-1 producing CPE was identified in the southern part of France [128] , and this was followed by another possible case of autochthonous acquisition [129] . NDM-1 has been found in K. pneumoniae by the use of realtime PCR directly in clinical samples [130, 131] , and with both phenotypic and molecular methods in different E. coli strains [132] .
The first KPC-producing isolate was identified from a patient transferred directly from New York in February 2005 [21] . After that, several reports were published related to KPC importation from the USA, Israel, and Greece [30, 133, 134] . In France, KPC-producing K. pneumoniae isolates remain rare, and, to date, have always been linked to patients transferred from a country where KPC enzymes are endemic (Israel, Greece, the USA and, recently, Italy) [135] . In some cases, hospital outbreaks have been described [135] ,
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interhospital dissemination mediated by a contaminated duodenoscope has also been reported [136, 137] . Most KPC producers have been nosocomial K. pneumoniae ST258 isolates and, to a lesser extent, E. coli and other enterobacterial species [135, 138] . Recently, the E. coli ST131 clone, the main clone responsible for CTX-M-15 diffusion in the community, was shown to harbour the bla KPC-2 gene along with the narrow-spectrum TEM-1 and OXA-9 b-lactamases, and the CTX-M-9 ESBL [139] . It was isolated from a urinary tract infection from a 64-year-old bedridden woman hospitalized in the gerontology ward of Lille University Hospital (France) [139] . Other class A carbapenemases have rarely been described in France. One IMI-1-producing E. cloacae [140] isolate and three IMI-2-producing Enterobacter asburiae isolates have recently been described (P. Nordmann, unpublished data).
Finally, the first OXA-48-producing isolate was a K. pneumoniae isolate identified in Paris in 2009 from the sputum of a patient transferred from Tunisia [141] . Subsequently, other OXA-48-producing K. pneumoniae isolates were found in patients transferred from countries around the Mediterranean sea (Turkey, Egypt, Algeria, Libya, Tunisia and, mostly, Morocco) [24, 59, 117, [142] [143] [144] . They were associated with several outbreaks [145] . OXA-48 is mainly found in unrelated K. pneumoniae clones detected across Europe and in E. coli isolates associated with clones previously linked with ESBLs in patients without a history of prior hospitalization [25] . However, very recently, an identical or clonally related K. pneumoniae OXA-48 producer was identified in France, The Netherlands, and Morocco [53] . A point mutant derivative, OXA-181, has been isolated from patients transferred from India [146] .
Since . These CPE isolates were mostly K. pneumoniae (59%), E. coli (22%), E. cloacae (12%), and various other enterobacterial species. The most prevalent carbapenemases were OXA-48 (51%), KPC (25%), VIM (9%), NDM (13%), IMI-1 (1%), and IMI-2 (1%). A link to foreign countries (patients transferred from foreign hospitals, previously hospitalized in a foreign country, and having undertaken recent travel to a foreign country) has been established for 76 of the cases (73%). These countries are mostly Greece, Morocco, and India. For 28 episodes, no link to a foreign country could be established, and among these, 21 involved OXA-48-like producers. These latter isolates were recovered in several parts of France, suggesting intra-country dissemination of these isolates, probably linked to the difficulty in detection of OXA-48-producing CPE isolates or to community dissemination from North Africa. These 104 episodes involved a total of 249 patients; 68 of them (29%) were infected and 170 (71%) were colonized. Most of the notifications related to single isolation of CPE, but epidemics involving up to 44 patients have also been described.
As the number of CPE cases in France remains low, in December 2010 the French health authorities implemented (Circulaire DGS/DGOS 06/12/2010 Contrô le des cas importés d'EPC; http://www.circulaires.gouv.fr/pdf/2010/12/ cir_32240.pdf) guidelines in order to build a 'line of defence' based on systematic screening for MDR bacteria for every patient transferred from foreign hospitals, or with a previous hospitalization in a foreign country, or who had undertaken a recent trip to a country with high prevalence, and to maintain contact isolation and strict hygiene measures for these patients, until screening results are available. Compliance with these rules would allow the containment of many episodes to a single case.
In Switzerland, the first CPE isolate was an SME-2-producing Serratia marcescens strain isolated in May 2006 at the University Hospital of Lausanne, Switzerland [147] . SME-2 is a clavulanic acid-inhibited class A carbapenemase, and its gene, bla SME-2 , is chromosomally encoded. Subsequently, a few cases of imported KPC producers have been described. A K. pneumoniae isolate producing KPC-2 was probably imported as a result of the transfer of a patient from Sicily, Italy, to the Neuchâtel public hospital in Switzerland in mid-2000 [148] . Four epidemiologically unrelated cases of KPCproducing K. pneumoniae were identified in Switzerland between May 2009 and November 2010; three cases were transferred from Italy (two KPC-3; one KPC-2) and one from Greece (KPC-2) [149] . During analysis of the mechanisms responsible for decreased susceptibility or resistance to carbapenems in several enterobacterial isolates recovered in 2009-2010 in Geneva University Hospitals, Switzerland, three patients were found to be positive for NDM-1-producing enterobacterial isolates (one with E. coli and K. pneumoniae, one with K. pneumoniae only, and one with Proteus mirabilis) [150] . This study constitutes the first identification of NDM-1 producers in Switzerland. Interestingly, patients from whom these NDM-1-producing isolates were recov-ered had a link to the Indian subcontinent or the Balkans. Finally, a few cases of OXA-48-producing K. pneumoniae identified in Geneva University Hospitals were probably transferred from North African countries (P. Nordmann and J. Schrenzel, unpublished data).
Belgium, Luxembourg, and The Netherlands
Although there is currently no mandatory reporting of carbapenem-resistant Gram-negative bacilli in Belgium, the National Reference Centre for MDR Enterobacteriaceae has been recording the proportion of CPE isolates detected. In 2007, only two isolates (8%) of those referred to this centre that were not susceptible to carbapanems were CPE, VIM-2 being the single carbapenemase found at that time. In 2010 and 2011, this situation rapidly changed, with 18 isolates of 94 (19.1%) referred in 2010 and 60 of 197 (30.5%) in referred 2011 being confirmed as CPE by the National Reference Centre. A variety of enzymes were found in these isolates, mainly OXA-48, VIM, and KPC. In 2010, sporadic NDM-producing isolates were detected for the first time in Belgium. The most frequent Enterobacteriaceae species by far was K. pneumoniae (69%), followed by Enterobacter cloacae (15%) and E. coli (6%). These isolates were found all over the country [151] . Although initial sporadic occurrence of CPE in Belgium was reported in patients returning from travel abroad [41, 104] , the majority of patients (70%) carrying CPE did not have a history of travel abroad or cross-border transfer, demonstrating potential secondary or autochthonous acquisition.
Today, the most prevalent carbapenemase in Enterobacteriaceae in Belgium by far is OXA-48 ( Fig. 3) [151] . Although most OXA-48-producing isolates have been found to represent asymptomatic cases in the urinary tract in elderly patients, a few cases of bacteraemia and of systemic infections have been recorded among patients in ICUs, and independent local outbreaks were reported in at least three hospitals in Belgium in 2010 and in 2011 [151] [152] [153] . In this country, carbapenemases were first detected in Acinetobacter (OXA-58), and later, in 2008, in K. pneumoniae (VIM-1), and were implicated in different nosocomial outbreaks, as in France and The Netherlands [41, [151] [152] [153] . A recent study highlighted this situation, with OXA-48 enterobacterial isolates also producing ESBLs (CTX-M-9, CTX-M-15, or SHV variants) [154] . Other carbapenemases from Belgium include KPC-2, which emerged within ST258 K. pneumoniae in 2009 in a patient transferred from Greece [104] , and NDM-1, which emerged in 2010 in nonclonally related Enterobacteriaceae from three patients who had been hospitalized in Pakistan, Montenegro, and Serbia/Kosovo [152] . NDM-1 was detected in all of the isolates, in addition to several ESBLs (CTX-M-15 and SHV-12), acquired AmpCs (CMY-16 and CMY-58), 16S rRNA methylases (ArmA and RmtB), and Qnr genes (qnrA6, qnrB1, and qnrB2). Screening for intestinal carriage of carbapenemases and strict infection control measures prevented secondary cases [152] .
The situation in The Netherlands is probably similar to that in Belgium, with OXA-48 now being one of the most prevalent carbapenemases [53, 155] . This enzyme was associated with an important outbreak at one hospital in Rotterdam, and was linked to a widespread ST395 K. pneumoniae clone also producing CTX-M-15 found in France that may have its origin in North Africa [156] . This clone has been found in a hospital in Morocco and also in the environmental setting [156] . Other carbapenemases found in The Netherlands are KPC-2 and NDM-1, both of them in K. pneumoniae isolates from patients with a history of travel to Greece and India, respectively [157] . In Luxembourg, as in Belgium and The Netherlands, sporadic cases of VIM-type carbapenemases (VIM-1 and VIM-27) have also been found in patients repatriated from hospitals in Greece [158] (Y. Glpczynski, unpublished data).
Germany and Austria
In the 2010 Annual report of the European Antimicrobial Resistance Surveillance Network (http://ecdc.europa.eu/ en/activities/surveillance/EARS-Net/database/Pages/database. aspx), one case was reported from Germany of invasive . Among CPE isolates, the majority were K. pneumoniae (n = 111), followed by E. coli (18) , Enterobacter cloacae (17), K. oxytoca (6), and C. freundii (5). The predominant carbapenemases in the different species were as follows: in K. pneumoniae, OXA-48 (43%), KPC-2 (23%), and KPC-3 (23%); in E. coli, OXA-48 (44%) and VIM-1 (28%); in Enterobacter cloacae, VIM-1 (71%); and in K. oxytoca, VIM-1 (83%). NDM-1 was found in only two K. pneumoniae isolates and in two E. coli isolates. Despite the dominance of OXA-48, for outbreaks in Germany only KPC-producing K. pneumoniae isolates have been reported, one of them also co-producing VIM-1 [159, 160] .
In Austria, few reports have recognized the presence of CPE [161] [162] [163] . One of them records emergence in the year 2005, with a remarkable increase in the number of involved patients in 2010. Carbapenem-resistant Enterobacteriaceae comprise K. pneumoniae, K. oxytoca and E. coli isolates with NDM, VIM, IMP, and KPC enzymes, showing the complexity of CPE. NDM-1 producers have been related to a Balkan origin.
Poland, the Czech Republic, Hungary, and Romania
According to the surveillance data collected by the National Reference Centre for Susceptibility Testing (NCRST) in Warsaw, most of the CPE isolates detected in Poland so far have been KPC producers. The first KPC-positive K. pneumoniae isolates reported were recovered in May 2008 in Warsaw. The isolates belonged to the ST258 clone, and produced KPC-2 together with the ESBL SHV-12. As the patient had not travelled for a long period before that time but had a history of previous hospitalization in Warsaw, it is likely that KPC producers had been present before this first report [164] .
Soon thereafter, the next organisms suspected of being KPC producers were sent to the NRCST by several hospitals, and by the end of 2008, 33 unique KPC-positive isolates from 32 patients in total had been confirmed. These were 30 K. pneumoniae and three K. oxytoca isolates, and were recovered in five Warsaw hospitals, three of which experienced outbreaks. The situation developed further in 2009, with 86 non-duplicate isolates from 82 patients, these being 84 K. pneumoniae and two E. coli isolates (the E. coli isolates were co-isolated with K. pneumoniae from a single patient). Most of the patients were hospitalized in 12 centres in the Warsaw area; moreover, three outpatients and one nursing home resident were diagnosed there as well. KPC producers were also identified in six other cities, in three cases following patient transfer from Warsaw, and in one case following patient transfer from New York. The molecular analysis of all isolates collected in 2008-2009 [165] revealed that 97.4% of the K. pneumoniae isolates were ST258, and only sporadic isolates belonged to ST11 or ST23. The two E. coli strains, being likely recipients of bla KPC -carrying plasmids from K. pneumoniae, were ST93 and ST224. Almost all of the isolates produced KPC-2; the only two exceptions, including the isolate from New York, expressed KPC-3. In all but one case, the bla KPC genes were located in the Tn4401a transposon [166] , carried by plasmids ranging from c. 48 to 250 kb. The most prevalent plasmids were conjugative IncFII K (c. 110-160 kb), identical or similar to the pKpQIL plasmid characterized in Israel [167] . The other prevalent plasmid was the non-typeable pETKp50 of c. 50 kb [168] , with low transfer potential. Significant groups of the isolates produced the ESBLs SHV-12 and/or CTX-M-3. In general, the analysis revealed a major role of K. pneumoniae ST258 and pKpQILlike molecules in the early spread of KPC-positive organisms. The diversity of the strains was attributed to several possible introductions of these into the country, their evolution during clonal dissemination, and transfer of plasmids [165] .
In 2010, the NRCST confirmed 153 unique KPC-producing isolates, mostly K. pneumoniae (one E. coli). This increase was mostly attributable to the continuous spread in central Poland (region Mazowsze, including Warsaw), from where 126 isolates from 32 healthcare institutions were collected (106 isolates from 26 sites in the Warsaw area alone). Of note was a local outbreak in another region (Świętokrzyskie) involving five hospitals in four locales, from which 19 unique isolates were confirmed in 2010. It is possible that wider implementation of the national guidelines for infection control (http://www.korld.edu.pl) helped to reduce the total number of cases confirmed to 104 in 2011. The Warsaw area continued to be the most affected; however, even more concern has been caused recently by a new outbreak in the region Podlasie (northeastern Poland), which started in February (possibly with a patient from the USA). By the end of 2011, the NRCST had confirmed 29 unique isolates from ten hospitals, including six centres in the main city Białystok, and, despite many efforts of the infection control specialists, the increase has been continuing to date (M. Gniadkowski, A. Baraniak, D. _ Zabicka, E. Tryniszewska, W. Hryniewicz, unpublished data).
Considering all of the data, it is clear that KPC spread has become the major issue in Poland. The total number of patients confirmed from 2008 to 2011 was 371, and it has been certainly underestimated. At least 58 hospitals in 34 locales have faced the problem, and even though the majority of these have apparently managed to control the situation, the notable number of institutions constitutes a reservoir for further spread. Of the three regional outbreaks observed, those with epicentres in Warsaw and Białystok are far from being successfully controlled.
There has been much less information concerning MBLproducing Enterobacteriaceae in Poland. The first such isolate reported, K. pneumoniae with VIM-4, was identified in 2006 in a hospital in Bydgoszcz [169] (I. Kern-Zdanowicz, M. Gniadkowski, unpublished data). In 2006-2008, the NRSCT confirmed eight MBL-positive isolates; however, in 2009, 2010, and 2011, these numbers were 22, 23, and 31, respectively (all of the isolates were collected from 39 hospitals in 24 cities). This increase may have been caused by the growing awareness of hospital laboratories regarding carbapenem resistance in enterobacteria and/or the actual dissemination of these organisms. Interestingly, the predominant species have been Enterobacter cloacae (50.0%), followed by S. marcescens (17.9%), K. oxytoca (16.7%), and K. pneumoniae (11.9%). Most of the isolates analysed so far have produced VIM-type MBLs (93.8%); three isolates had IMP types, and recently the first E. coli isolate with an NDM-like enzyme was recovered in Warsaw from a patient who had been moved from a hospital in the Congo (M. Gniadkowski, J. Fiett, D. _ Zabicka, K. Filczak, W. Hryniewicz, unpublished data).
In the Czech Republic, the situation regarding CPE is much better than in Poland; however, in 2011, the National Reference Laboratory for Antibiotics in Prague observed significant increases in the numbers of both MBL-positive and KPC-positive cases (J. Hrabák, P. Urbášková, H. Ž emličková, personal communication). Regarding MBL producers, from 2009 to 2010, five VIM-1-producing isolates (four S. marcescens and one Enterobacter cloacae) were recovered from sporadic infections in Opava, Havířov (the area of Ostrava), and from a large hospital in Prague (three cases). Interestingly, in 2011, this Prague hospital recorded eight new cases, but most of these involved K. pneumoniae isolates with another bla VIM-1 -carrying integron, indicating the new emergence of VIM-1 producers in that centre. Additionally, two other hospitals reported MBL-positive K. pneumoniae, including one VIM-1 producer imported by a patient from Greece. Also from Greece, the first Czech patient infected with a K. pneumoniae ST258 KPC-2 producer was admitted to the Havířov hospital in July 2009 [170] . In 2011, 11 unique KPC-producing K. pneumoniae isolates were identified in five hospitals in Prague, including six isolates from an outbreak in one hospital with a patient returning from Italy. Of the remaining five cases, three were linked to the previous hospitalization in Greece.
In Hungary, a local outbreak of KPC-2-producing and SHV-12-producing K. pneumoniae ST258 was reported in 2008-2009 in the north-eastern part of the country; this started with a patient who had been hospitalized in Greece [171] . In 2009, single isolates of K. pneumoniae ST11 and K. oxytoca carrying the same integron with the bla VIM-4 gene cassette were identified in two different hospitals [145] . KPC-producing Enterobacteriaceae have been recently detected in Romania (Y. Carmeli, unpublished data), as well as cases of NDM producers abroad associated with travellers to this country (Ø. Samuelsen, unpublished data).
UK and the Republic of Ireland
There is no mandatory reporting of carbapenem-resistant Gram-negative bacilli in the UK. However, the Antibiotic Resistance Monitoring and Reference Laboratory (ARMRL) of the Health Protection Agency (HPA) encourages referral (see http://www.hpa.org.uk/ProductsServices/InfectiousDiseases/LaboratoriesAndReferenceFacilities/AntibioticResistance MonitoringAndReferenceLaboratory/), and seeks carbapenemases in these: (i) if they are confirmed to be resistant to at least one carbapenem; and (ii) if that resistance cannot be attributed to a non-carbapenemase mechanism by interpretative reading of the complete antibiogram. The HPA, together with the UK Government's ARHAI Committee, has issued 'Advice on Carbapenemase Producers: recognition, infection control and treatment' (http://www.hpa.org.uk/web/HPAweb File/HPAweb_C/1294740725984).
The first confirmed isolate in the UK with an acquired carbapenemase was an Acinetobacter isolate with IMP-1 in 2000 [172] , but this genus has not proved to be a frequent host of metalloenzymes in the UK. The first confirmed CPE isolates were referred to the ARMRL in 2003. These were an isolate of Enterobacter with KPC-4, and two isolates of Klebsiella with IMP-type and VIM-type enzymes. Fewer than five CPE isolates were confirmed in the UK in each of the next 4 years (2004-2007) . They were mostly isolated from patients with a history of travel and hospitalization, often following road traffic accidents, in endemic areas, e.g. KPC producers from Greece or Israel [173] , VIM-positive klebsiellae from Greece, and an OXA-48 producer from Turkey. Although Enterobacteriaceae with KPC enzymes were most commonly referred, the numbers are skewed by an ongoing problem in north-western England, which involves the transmission of pKpQIL-like plasmids [167] , encoding KPC-2 among different bacterial strains, principally of K. pneumoniae, but with spread also to E. coli and Enterobacter (N. Woodford and D. M. Livermore, unpublished data). Referrals from this region accounted for c. 75% of the UK's total number of KPC-positive isolates, with many of these isolates being obtained from faecal screens rather than infections. Similarly, a small number of hospitals in one region shared an ongoing outbreak of VIM-positive klebsiellae, which also extended to the community, and these accounted for the majority of the UK total with this carbapenemase. In 2008, there was an outbreak, centred on a London renal unit, caused by K. pneumoniae with OXA-48; there was a dominant outbreak strain, but with horizontal transfer of an OXA-48-encoding plasmid to other strains (Thomas et al., 49th ICAAC, 2009, Abstract C2-648).
Although less numerous than KPC producers, bacteria with NDM enzymes [8, 23] have the widest distribution in the UK; 55 laboratories referred at least one producer after the enzyme was first detected in 2008, as compared with 42 referring isolates with KPC enzymes and 22 with VIM types (Fig. 4) .
The UK has recorded more NDM cases than any other European country [116] , and, to the end of 2011, genes encoding NDM enzymes had been detected in 138 isolates of Enterobacteriaceae and also in 11 A. baumannii isolates, collectively from 115 patients. Multiple species with NDM enzymes were isolated from several patients, which is consistent with either in vivo transfer of a resistance plasmid or initial colonization/infection by more than one species.
There is no coordinated epidemiological follow-up for these cases, and the HPA has a travel history, albeit limited, for only 53/115 (46%) patients with NDM-positive isolates, 32 (60%) of whom were known to have travelled to or had healthcare contact in India (n = 25) or Pakistan (n = 7).
The antibiograms of carbapenemase producers are highly variable, and range from extreme multiresistance to resistance only to b-lactams. Many K. pneumoniae isolates from the large KPC cluster in north-western England remain susceptible to aminoglycosides and ciprofloxacin, and, as noted earlier, producers of OXA-48-like enzymes may remain susceptible to oxyimino-cephalosporins unless they have other co-resident mechanisms, such as ESBLs or AmpC enzymes. In 2011 analyses, only colistin was active against >90% of all UK carbapenemase producers. Tigecycline was active against some producers, notably vs. E. coli, but a breakthrough bacteraemia caused by an NDM-positive E. coli isolate that became resistant to tigecycline during on-label use of the drug has been described [174] . In short, therapy of patients infected by carbapenemase-producing bacteria must be guided by the resistance profile of the causative isolate, which may remain susceptible to less commonly tested agents [175] .
The first published report of CPE in Ireland was of a KPC enzyme in a K. pneumoniae isolate recovered in 2009 from a sputum sample collected 48 h after hospital admission in a patient with exacerbation of chronic obstructive pulmonary disease. No association with travel abroad was demonstrated in this patient [176] . The second one reported the emergence of a VIM-1-producing K. pneumoniae isolate in 2010 in a patient transferred from Greece [177] . Subsequently, there has been regional spread of KPC producers (Condon et al., 21st ECCMID, 2011, Abstract P73), with isolates being detected in four hospitals (D. Morris, personal communication). It is of note that KPC-2 has also been detected in an E. coli isolate belonging to the uropathogenic ST131 clone [178] 
Nordic and Baltic Countries
During the early 2000s, there were no reports on CPE from any of the Nordic countries. Approaching the end of the decade, and particularly in the last 3 years, the number of cases has increased rapidly, but still remains very low. In most of the countries, laboratories are encouraged to send suspected CPE isolates to reference laboratories, but the number of cases is too low for it to be meaningful to consider denominator data. In all of the Nordic countries, there were, in total, 41 cases of CPE in 2011. There have been few cases of invasive infections caused by CPE, although one case of invasive VIM-producing K. pneumoniae, one case of KPC-producing K. pneumoniae and one case of invasive NDM-1-producing E. coli have been observed over a 5-year period [42, 58, 180] .
There have been no reports so far of CPE from the Baltic countries and from Iceland, whereas all of the other Nordic countries have experienced cases. In general, the awareness of CPE is high in Nordic hospitals, and active faecal screening is conducted in many locations on patients with a history of recent travel or hospitalization abroad.
The most prevalent class of carbapenemases observed in the Nordic countries has been KPC, and almost exclusively in K. pneumoniae. In total, 14 cases have been identified in Norway, 14 cases in Sweden, three cases in Denmark, and five cases in Finland. KPC-2 has most commonly been identified, but cases of KPC-3 have also been demonstrated. The cases have mostly been associated with strain imports from Greece, Israel, the USA, or Italy; however, subsequent cases of nosocomial transfer and a small long-term outbreak have been observed [42] (Ø. Samuelsen, unpublished data). Mostly, KPC enzymes have been found in K. pneumoniae of ST258 or in STs belonging to the same clonal complex [42, [181] [182] [183] [184] . The plasmid epidemiology has been less well characterized, and at present it has not been established which plasmid types are mainly associated with the spread of KPC. Finally, of the minor class A carbapenemases, GES-14 and IMI-1/2 have been detected in Finland in K. pneumoniae (GES-14) and Enterobacter cloacae (IMI-1/-2).
MBLs are the second most common group of enzymes produced by CPEs, and, historically, VIM has been the most common variant. Since the first case of NDM-1 in Sweden in 2008 [8] , this MBL has become as common as VIM, especially in Sweden (C. G. Giske, upublished data). The cases have usually been associated with recent travel to India [8, 145] or the Balkan region [182] , or have been connected to Middle Eastern countries or even Thailand (C. G. Giske, unpublished data) and Romania (Ø. Samuelsen, unpublished data). Many of the VIM-producing K. pneumoniae isolates belong to international clonal complexes such as ST147, and association with IncN-type plasmids is common [58] . The NDM-producing K. pneumoniae isolates have been associated with ST14, ST11, and ST525 [8, 177] (Ø. Samuelsen unpublished data), whereas the plasmid epidemiology has been less well studied, with the exception of the identification of NDM-1 on an IncA/C plasmid in an isolate from Denmark [181] . The number of cases identified in the Nordic countries so far are as follows: Norway, seven cases (four VIM and three NDM-1); Sweden, 16 cases (six VIM and ten NDM-1); Denmark, six cases (three VIM and three NDM-1); and Finland, seven cases (four VIM and three NDM-1).
OXA-48-like enzymes are emerging as an important third group of carbapenemases. In the Nordic countries, most of the cases with OXA-48 or OXA-48-like enzymes have been associated with travel or hospitalization in North Africa and Middle Eastern countries, similar to what has been reported from other European countries. No published data are available on STs and plasmid characterization so far. OXA-48-like enzymes have been detected so far in Finland (n = 10), Denmark (n = 7), Sweden (n = 4), and Norway (n = 1), including several cases in E. coli (C. G. Giske, Ø. Samuelsen, A. M. Hammerum, J. Jalava, unpublished data).
Conclusions
Carbapenemases in Enterobacteriaceae are mostly plasmidencoded, which largely explains their common association with other resistance markers and their multidrug resistance patterns. The prevalence of the CPE is variable across Europe; a high prevalence can be found in Greece, Italy, Turkey, and Israel, whereas a low prevalence is still reported in Nordic countries, Switzerland, Germany, and the Czech Republic. The type of CPE depends on the country, and might be associated with historical/cultural relationships and exchange of populations with other countries of high prevalence. Crossborder transfer of patients, travel, medical tourism and refugees might also play an important role. This is particularly true for the spread of OXA-48 in France and in Belgium from North Africa, and in Germany, probably from Turkey, or the identification in UK of NDM-1 producers of Indian origin. The clearly increasing frequency of CPE in recent last years could be related to the increasing prevalence of OXA-48 producers in many European countries and the exportation of KPC producers from Greece and Italy to other European countries. In many cases, the spread of CPE results from hospitalization abroad. More important are the cases without importation links, which may represent communityacquired and/or autochthonous cases. In addition, although a polyclonal situation has been observed for CPE in many countries, some widespread clones have also been detected across Europe (KPC-2-producing K. pneumoniae ST258 or OXA-48-producing K. pneumoniae ST395).
The future trend of this CPE epidemic will be one of increase, as the reservoirs of carbapenemase producers are growing worldwide. Although dissemination of CPE mainly occurs among hospitalized patients (K. pneumoniae), community acquisition is increasing (especially for OXA-48 producers). A well-concerted effort all over Europe is clearly needed to prevent the further spread of CPE, and hence to avoid an uncontrollable situation as can now be observed worldwide for CTX-M ESBL producers. 
